rs12946510 — IKZF3 IKZF3 17q21 FOXO1-enhancer variant

Regulatory variant in a FOXO1-binding enhancer element flanking the IKZF3 gene at 17q21; the C allele maintains FOXO1/MEF2A binding and is associated with elevated ORMDL3, GSDMB, and IKZF3 expression, higher asthma susceptibility, and risk for several autoimmune conditions; the T allele disrupts these binding sites, reducing expression of all three genes and is protective for asthma but associated with increased risk for multiple sclerosis and IBD

See your personal result for IKZF3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IKZF3 17q21 — The FOXO1-Enhancer Dial Between Asthma and Autoimmunity

At chromosome 17q21 sits one of the most consequential regulatory loci in human immunology — a ~130-kb haploblock containing ORMDL311 ORMDL3
Orosomucoid-like protein 3; a transmembrane protein anchored in the endoplasmic reticulum that regulates sphingolipid biosynthesis, ICAM-1 expression, and the unfolded protein response, all of which influence airway epithelial responses to viral infection and allergen challenge, GSDMB (gasdermin B), IKZF3 (Aiolos), ZPBP2, and GSDMA. Genetic variants across this locus associate with childhood asthma, allergic rhinitis, multiple sclerosis, inflammatory bowel disease, primary biliary cholangitis, and ankylosing spondylitis — a remarkable span of inflammatory phenotypes controlled by a single regulatory neighbourhood.

rs12946510 at GRCh38 chr17:39,756,124 is an intergenic variant that sits within a chromatin-accessible enhancer element flanking the IKZF3 gene on the distal end of the 17q21 haploblock. It is one of the few 17q21 variants with direct experimental validation of its functional mechanism.

The Mechanism

The C allele at rs12946510 maintains a FOXO1 binding motif22 FOXO1 binding motif
Forkhead box protein O1 (FOXO1) is a transcription factor essential for B cell development, germinal centre reactions, and immune tolerance; it binds DNA at the sequence GTAAACA; the C allele of rs12946510 preserves this sequence while the T allele disrupts it, as well as binding sites for MEF2A and MEF2C (myocyte enhancer factor family members critical for lymphocyte differentiation). The T allele disrupts all three of these transcription factor binding sites, reducing the enhancer's activity and consequently lowering expression of ORMDL3, GSDMB, and IKZF3 in immune cells.

CRISPR/Cas9 editing33 CRISPR/Cas9 editing
Ustiugova et al. Biochim Biophys Acta Mol Basis Dis 2023; isogenic T helper cell lines bearing CC, CT, or TT genotypes at rs12946510 were created and compared for gene expression and cellular activation profiles provided direct causal proof: cells carrying the T allele showed lower IKZF3 and ORMDL3 expression and reduced cellular activation. This makes rs12946510 one of the few 17q21 variants with experimentally validated functional consequence rather than just statistical association.

The consequence of this expression difference is tissue-context dependent. Higher ORMDL3 in airway epithelial cells increases ICAM-1 expression (the rhinovirus receptor), amplifies the unfolded protein response, and elevates sphingolipid signalling, collectively priming the airway for exaggerated inflammatory responses to viral and allergen challenge. By contrast, IKZF3/Aiolos normally suppresses germinal centre hyperactivation and IgE overproduction — the T allele's lower IKZF3 expression removes this brake on B cell responses, which may underlie its association with autoimmune conditions where excessive immune activation is the pathological driver.

The Evidence

The GABRIEL consortium GWAS44 GABRIEL consortium GWAS
Moffatt et al. NEJM 2010; 10,365 asthma cases and 16,110 controls across 10 European populations; genome-wide significant signals at the 17q21 locus including the IKZF3/ORMDL3 region established the 17q21 haploblock as the most replicated childhood asthma susceptibility locus, with variants across this region — including the IKZF3 regulatory position at rs12946510 — consistently associated with asthma risk. CRISPR/Cas9 functional validation subsequently confirmed that T allele carriers at rs12946510 have lower ORMDL3 and IKZF3 expression, providing the mechanistic basis for reduced asthma susceptibility.

The systematic analysis of functional SNPs in 17q12-2155 systematic analysis of functional SNPs in 17q12-21
Ustiugova et al. Genes 2019; bioinformatic prediction of transcription factor binding across all 17q21 SNPs; reporter assays in three cell types; rs12946510 had the strongest functional prediction of any variant tested identified rs12946510 as the variant with the greatest predicted impact on transcription factor binding in the entire 17q21 locus — with over 20-fold changes in MEF2A, MEF2C, FOXO1, SOX3, and SOX6 binding affinity. The primary biliary cholangitis study66 primary biliary cholangitis study
Hitomi et al. Sci Rep 2017; eQTL analyses of rs12946510 in whole blood and spleen; T allele significantly associated with lower ORMDL3 and GSDMB expression confirmed that the T allele's functional consequences are detectable in blood at the level of gene expression.

For multiple sclerosis, RRMS patients from Serbia77 RRMS patients from Serbia
Stefanovic et al. J Neuroimmunol 2020; TT genotype nominal MS association; decreased ORMDL3 and GSDMB mRNA levels in TT homozygotes vs non-TT patients demonstrated the inverse phenotype: when the FOXO1 binding site is disrupted (T allele), reduced IKZF3/Aiolos expression may impair normal regulatory brake on B cell activation, predisposing to autoimmune demyelination.

Practical Implications

CC homozygotes carry both copies of the FOXO1-binding, higher-expression haplotype — the configuration associated with increased ORMDL3/GSDMB-driven airway inflammation and the highest asthma susceptibility at this locus. This variant is most clinically relevant for childhood-onset asthma and virus-triggered wheeze, where ORMDL3's role in ICAM-1 expression amplifies rhinovirus susceptibility. Tracking pulmonary function objectively during respiratory viral infections and high-allergen seasons is the highest-yield monitoring action for CC carriers.

TT homozygotes, while protected at this locus from atopic airway disease, carry the FOXO1 binding-disrupted haplotype and the consequent lower IKZF3/Aiolos expression — positioning them at the autoimmune end of the 17q21 spectrum (MS, IBD, PBC associations).

Interactions

rs12946510 operates within the same 17q21 haploblock as rs12936231 (the strongest ORMDL3 eQTL in blood), rs7216389 (the canonical childhood asthma GWAS hit), and rs2872507 (IKZF3 autoimmune variant). These variants are partly correlated but represent distinct functional positions within the 130-kb regulatory region. Carriers of risk haplotypes at multiple 17q21 positions face additive ORMDL3 expression burden, amplifying airway inflammatory priming beyond any single variant alone.

rs2872507 (IKZF3, chr17:39,884,510) is the 17q21 variant most studied for autoimmune associations — its A allele is a risk factor for rheumatoid arthritis and Crohn's disease. Individuals carrying both rs12946510-CC and rs2872507-AA represent the highest-ORMDL3, highest asthma-risk haplotype configuration at 17q21, while those carrying T alleles at rs12946510 alongside autoimmune-risk alleles at rs2872507 may face the autoimmune end of the 17q21 disease spectrum.

Genotype Interpretations

What each possible genotype means for this variant.

TT FOXO1-Site Disrupted Normal

Both copies carry the T allele with disrupted FOXO1 binding — lowest ORMDL3 expression and most protected configuration against asthma at this 17q21 locus

The TT genotype at rs12946510 means both copies of the 17q21 FOXO1 regulatory enhancer are in the disrupted configuration. Since FOXO1 normally activates this enhancer to drive ORMDL3, GSDMB, and IKZF3 expression, TT homozygotes show the lowest constitutive and inducible levels of these genes in leukocytes and presumably airway epithelial cells. ORMDL3 regulates ICAM-1 expression (the rhinovirus receptor), sphingolipid synthesis, and the unfolded protein response — so lower ORMDL3 reduces several of the molecular amplifiers of virus-triggered and allergen-triggered asthma exacerbations. The IKZF3/Aiolos protein normally suppresses spontaneous germinal centre formation and IgE overproduction; its lower level in TT carriers may subtly relax this suppression, which could underlie the TT genotype's associations with MS and IBD in other studies. The net clinical picture for most TT individuals is favourable respiratory health at the 17q21 locus.

CT Intermediate ORMDL3 Expression Intermediate

One C and one T allele — intermediate ORMDL3/GSDMB expression with moderately elevated asthma susceptibility at this 17q21 locus

The 17q21 locus behaves additively across genotype groups for ORMDL3 expression and asthma risk — each additional C allele at rs12946510 increases FOXO1-driven enhancer activity and consequently raises the expression of all three downstream genes. As a CT heterozygote, your ORMDL3 levels in blood cells sit between CC and TT; this is the intermediate expression state. ORMDL3's role in airway inflammatory priming — via ICAM-1 upregulation (rhinovirus docking), sphingolipid pathway dysregulation, and ER stress induction — means moderately elevated ORMDL3 translates to a modestly elevated sensitivity to viral and allergen triggers for wheeze and early-onset asthma. The T allele in this genotype partially moderates the enhancer activity compared to CC homozygosity.

CC Full FOXO1-Enhancer Activation High Risk

Both copies carry the C allele — highest ORMDL3/GSDMB/IKZF3 expression and greatest asthma susceptibility at this 17q21 locus

In CC homozygotes, both copies of the 17q21 IKZF3 regulatory enhancer retain full FOXO1 and MEF2A/C binding capacity, driving the highest constitutive and inducible ORMDL3 expression of the three genotypes. ORMDL3 acts at multiple convergent points in airway inflammatory pathophysiology: it regulates serine palmitoyl-CoA transferase (inhibiting sphingolipid synthesis), activates ATF6α (an unfolded protein response branch affecting airway epithelial integrity), upregulates ICAM-1 (enhancing rhinovirus docking on epithelial cells), and modulates IL-6 and CXCL10 production. GSDMB, the co-regulated gasdermin family member, contributes to epithelial pyroptosis and airway remodelling. Together, elevated expression of both proteins primes the CC homozygote's airway for exaggerated inflammatory cascades following viral or allergen exposure.

From an immune-regulation standpoint, CC homozygotes also have the highest IKZF3/Aiolos expression. While Aiolos normally helps suppress spontaneous germinal centre formation and limit IgE overproduction, its elevated levels in CC carriers create the opposite risk profile from the autoimmune-susceptible TT genotype — CC carriers lean toward atopic amplification rather than autoimmune dysregulation.

The clinical context where this matters most is early-childhood asthma: the 17q21 locus was initially identified in childhood-onset asthma GWAS, and ORMDL3 expression in cord blood and neonatal blood already stratifies risk for early wheeze. CC status at rs12946510 contributes additively to the 17q21 expression burden alongside other locus variants such as rs12936231 and rs7216389.